Please try another search
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, blepharitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, acute glaucoma, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. It had various drug assets in its portfolio. The company was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.
Name | Age | Since | Title |
---|---|---|---|
Ting Yuk Wu | 67 | 2020 | Independent Non-Executive Director |
Ye Liu | 50 | 2018 | CEO & Executive Director |
Yumeng Wang | 31 | 2021 | Non-Executive Director |
Yiran Huang | 67 | 2020 | Independent Non-Executive Director |
Yanling Cao | 38 | 2019 | Non-Executive Director |
Zhenyu Zhang | 46 | 2022 | Independent Non-Executive Director |
Zhaopeng Hu | 50 | 2020 | Chief Development Officer & Executive Director |
Lian Yong Chen | 60 | 2018 | Non-Executive Chairman of the Board |
Wei Li | 51 | 2018 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review